Furthermore, many studies, which have evaluated the efficacy and safety of other pyrotinib‐containing regimens in the first‐line treatment for HER2‐positive MBC and (neo)adjuvant therapy for early or locally advanced HER2‐positive breast cancer, have obtained satisfactory preliminary results.26, 27, 28, 29. Here, ERBB2 is linked to breast carcinoma.